Log in to search using one of your social media accounts:

 

GSE31335 Characterization of the small RNAome in acute myeloid leukemia and discovery of novel small RNA species by deep sequencing (Illumina)

Contributors : Jun Wang ; Jacek Marzec ; Floriana Manodoro ; Charles Mein ; Alessandra Curtotti ; Bryan D Young ; Silvana DebernardiSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Homo sapiensWe used small RNA seq (Illumina) to characterise and quantify the miRNA and small non-coding (snc)RNA transcriptome of 38 libraries of size-fractionated RNA obtained from AML patients and normal bone marrow. We detected the expression of 765 known miRNAs and 2554 uniquely located species of sncRNAs. A total of 575 potential miRNA candidate hairpins were identified. We also identified 37 C/D Box and 51 H/ACA Box, potential novel snoRNAs.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by high throughput sequencing Homo sapiens Source Type: research

Related Links:

AbstractDecitabine (Dacogen®), a deoxynucleoside analogue of cytidine that selectively inhibits DNA methyltransferases, provides beneficial effects in adults with newly diagnosed acute myeloid leukaemia (AML) not eligible for standard induction chemotherapy. In DACO-016, the registrational phase 3 clinical trial in this patient population, intravenous decitabine provided a clinically meaningful improvement in median overall survival (OS) relative to treatment choice (cytarabine or best supportive care) of 2  months (7.7 vs 5.0 months), as well as significant improvements in other efficacy outcomes. After a fu...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 22 September 2017 Source:Best Practice & Research Clinical Haematology Author(s): Richard M. Stone For 4 decades, new agents had not been approved for use in treating acute myeloid leukemia (AML). The long dry spell was broken in 2017, however, with the approval or recommendation for approval of several agents: midostaurin for addition to chemotherapy in mutant FLT3 patients undergoing intensive chemotherapy, enasidenib in advanced mutant IDH2 patients, CPX-351 in secondary AML patients, and gemtuzumab ozogamicin in conjunction with standard chemotherapy in AML. This review surveys t...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 22 September 2017 Source:Best Practice & Research Clinical Haematology Author(s): Jacob M. Rowe Numerous advances have been made in the biology and treatment of acute myeloid leukemia (AML) in 2017. These include the integration of the assessment of minimal residual disease (MRD) into clinical practice, the approval and near approval of new agents, improvement in therapy for older patients, and the development of a number of promising new agents, including IDH inhibitors, a Hedgehog signaling pathway inhibitor, and a histone deacetylase inhibitor. In addition, the concept of chemothe...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 22 September 2017 Source:Best Practice & Research Clinical Haematology Author(s): Frederick R. Appelbaum For younger patients with intermediate- or high-risk acute myeloid leukemia (AML) in first remission, allogeneic hematopoietic cell transplantation (HCT) offers the best chance of cure and therefore is the treatment of choice. The role of allogeneic HCT in the treatment of older patients is less well defined. In this review, four issues concerning the role of HCT in the treatment of older AML patients will be addressed: the frequency of allogeneic HCT in the older AML population i...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 22 September 2017 Source:Best Practice & Research Clinical Haematology Author(s): Hillard M. Lazarus, Najla El Jurdi Improving long-term outcomes of adult acute myeloid leukemia (AML) patients remains a challenge. Major scientific and clinical advances have led to a better understanding of the disease biology, and the majority of patients achieve a complete remission (CR) after induction therapy. Relapse risk, however, remains considerable and is the leading cause of death in this patient population. Significant efforts to improve outcomes emphasize use of post-remission therapies su...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Conclusion A single-institutional retrospective analysis found no significant differences in outcomes using GCLAC or CLAG for rrAML patients, though formal comparisons should be performed in a randomized clinical trial. The cost of GCLAC was higher than CLAG which should be considered when evaluating salvage chemotherapy options.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOur data indicate that KMT2C ELs are associated with specific genetic features and that SPRY4 ELs may add prognostic information.This article is protected by copyright. All rights reserved.
Source: European Journal of Haematology - Category: Hematology Authors: Tags: Original Article Source Type: research
Authors: Brown AEC Abstract Refusing treatment for potentially curable childhood cancers engenders much discussion and debate. I present a case in which the competent parents of a young Amish child with acute myeloid leukemia deferred authority for decision making to the child's maternal grandfather, who was vocal in his opposition to treatment. I analyze three related concerns that distinguish this case from other accounts of refused treatment. First, I place deference to grandparents as decision makers in the context of surrogate decision making more generally. Second, the maternal grandfather's ardent refusal of...
Source: Journal of Clinical Ethics - Category: Medical Ethics Tags: J Clin Ethics Source Type: research
Acute myeloid leukemia (AML) is a blood cancer that is poorly responsive to conventional cytotoxic chemotherapy and a diagnosis of AML is usually fatal. More effective and better-tolerated therapies for AML are desperately needed. Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are one of the most frequently observed genetic defects in AML. FLT3 tyrosine kinase inhibitors have shown impressive anti-leukemic activity in clinical trials, however, sustained remissions using these inhibitors as monotherapy have not been achieved.
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research
tos &M Järås
Source: Leukemia - Category: Hematology Authors: Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Databases & Libraries | Genetics | Leukemia